Correia Ana Salomé, Vale Nuno
OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
Pharmaceuticals (Basel). 2021 Sep 16;14(9):930. doi: 10.3390/ph14090930.
Mirtazapine belongs to the category of antidepressants clinically used mainly in major depressive disorder but also used in obsessive-compulsive disorders, generalized anxiety, and sleep disturbances. This drug acts mainly by antagonizing the adrenergic α2, and the serotonergic 5-HT2 and 5-HT3 receptors. Neuropsychiatric symptoms, such as depression and agitation, are strongly associated with Alzheimer's disease, reducing the life quality of these patients. Thus, it is crucial to control depression in Alzheimer's patients. For this purpose, drugs such as mirtazapine are important in the control of anxiety, agitation, and other depressive symptoms in these patients. Indeed, despite some contradictory studies, evidence supports the role of mirtazapine in this regard. In this review, we will focus on depression in Alzheimer's disease, highlighting the role of mirtazapine in this context.
米氮平属于抗抑郁药类别,临床上主要用于治疗重度抑郁症,但也用于强迫症、广泛性焦虑症和睡眠障碍。这种药物主要通过拮抗肾上腺素能α2以及血清素能5-HT2和5-HT3受体发挥作用。神经精神症状,如抑郁和激动,与阿尔茨海默病密切相关,会降低这些患者的生活质量。因此,控制阿尔茨海默病患者的抑郁至关重要。为此,米氮平这类药物对于控制这些患者的焦虑、激动和其他抑郁症状很重要。事实上,尽管有一些相互矛盾的研究,但证据支持米氮平在这方面的作用。在这篇综述中,我们将聚焦于阿尔茨海默病中的抑郁,突出米氮平在这种情况下的作用。